ESR1 and breast cancer: Interestingly, fulvestrant binds to ERα promoting receptor ubiquitination and degradation by the proteasome, thus is an alternative therapy in the treatment of ER+ BC patients under endocrine therapy resistance and has been approved for the treatment of metastatic ERα+ BC following antiestrogen therapy [10,11].